Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 407
- Registration Number
- NCT01907854
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain
Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1DiabetesHealthy
- Interventions
- Other: No treatment given
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 61
- Registration Number
- NCT01900834
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Princeton, New Jersey, United States
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed
- Conditions
- Diabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- Drug: other injectable antidiabetic treatment regimens
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2446
- Registration Number
- NCT01892319
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Stevenage, United Kingdom
Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: biphasic insulin aspart 50Drug: biphasic human insulin 50
- First Posted Date
- 2013-07-03
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 161
- Registration Number
- NCT01892020
Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 952
- Registration Number
- NCT01890993
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 813
- Registration Number
- NCT01885208
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Rotherham, United Kingdom
A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 458
- Registration Number
- NCT01880736
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokkaichi-shi, Mie, Japan
A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
Completed
- Conditions
- Congenital Bleeding DisorderGlanzmann's Disease
- Interventions
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4
- Registration Number
- NCT01876745
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Other: No treatment given
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2092
- Registration Number
- NCT01877200
A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 46
- Registration Number
- NCT01868542
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Daejeon, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath